GATA3 and breast cancer: Our data, therefore, support the possible clinical utility of incorporating GATA3 IHC analysis into routine practice as an adjunct to standard IHC panel, in order to further risk-stratify BC patients at a remarkably low cost when compared to multigene prognostic tests.